Abbott Laboratories halts new drugs to Thailand
Adjust font size:
Manufacturing News, Source : The Manufacturer US
Published : 13 Mar 2007 21:51
They’ll be in negotiations later this week, but until then, Abbott Laboratories has pledged not to launch new medicinces in Thailand.
This after Thailand’s Ministry of Public Health issued a compulsory license last month which, in essence, voids Abbott’s patent on its HIV antiviral Kaletra.
The compulsory license allows Thai industry to produce a lower-cost alternative to Kaletra. Thailand is framing this as a response to a “national emergency”: nearly 600,000 Thais live with HIV, and the government funds medical treatment. A generic Kaletra would cost about $120 per month per patient, versus $347 for Kaletra.
Thailand has similarly suspended the patent on Plavix, Sanofi-Aventis’ blood thinner.
Comments on this story
click here to add a comment
You must be registered & logged in to add comments
already have an account and just want to login?
Related Content
Guest Editorial: Checklist - Seven Recommendations for Improved Profits
by Abbott A. Imberman, PhD, Professor of...
more…
FKI LOGISTEX OPENS NORTH AMERICAN TECHNOLOGY & EDUCATION CENTER (TEC)
(St. Louis, Missouri, USA: July 10, 2007) FKI...
more…
Guess selects the tradecard platformand SourceView suite to optimize global trade
NEW YORK, July 10, 2007 – TradeCard Inc., the...
more…
Kimberly-Clark Professional Crosses Final Touchless Frontier With Introduction of First Electronic Bath Tissue Dispenser
ROSWELL, Ga. (July 9, 2007) – Kimberly-Clark...
more…
Boeing Celebrates the Premiere of the 787 Dreamliner
EVERETT, Wash., July 08, 2007 -- Today, Boeing...
more…
no comments yet...